TuisNVAX • NASDAQ
add
Novavax Inc
Vorige sluiting
$8,48
Dagwisseling
$8,02 - $8,36
Jaarwisseling
$5,01 - $11,50
Markkapitalisasie
1,32 mjd USD
Gemiddelde volume
4,60 m
P/V-verhouding
3,54
Dividend-opbrengs
-
Primêre beurs
NASDAQ
In die nuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Jun. 2025info | J/J-verandering |
|---|---|---|
Inkomste | 239,24 m | -42,42% |
Bedryfskoste | 53,28 m | -53,23% |
Netto inkomste | 106,51 m | -34,41% |
Netto winsgrens | 44,52 | 13,92% |
Wins per aandeel | 0,62 | -37,37% |
EBITDA | 113,23 m | -34,63% |
Effektiewe belastingkoers | 0,88% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Jun. 2025info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 612,30 m | -41,66% |
Totale bates | 1,34 mjd | -26,51% |
Totale aanspreeklikheid | 1,30 mjd | -42,28% |
Totale ekwiteit | 37,62 m | — |
Uitstaande aandele | 162,42 m | — |
Prys om te bespreek | 36,87 | — |
Opbrengs op bates | 20,09% | — |
Opbrengs op kapitaal | 126,06% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Jun. 2025info | J/J-verandering |
|---|---|---|
Netto inkomste | 106,51 m | -34,41% |
Kontant van bedrywe | -127,46 m | -140,56% |
Kontant van beleggings | 111,10 m | 129,81% |
Kontant van finansiering | -1,04 m | -100,40% |
Netto kontantverandering | -9,50 m | -104,76% |
Beskikbare kontantvloei | -124,92 m | -122,15% |
Meer oor
Novavax, Inc., based in Gaithersburg, Maryland, develops vaccines to counter infectious diseases. The company's first and only commercial product is the Novavax COVID-19 vaccine. The company is also developing vaccines for influenza, respiratory syncytial virus, avian flu, shingles, Clostridioides difficile, and malaria.
Novavax also develops proprietary immune-stimulating saponin-based immunologic adjuvants at a wholly owned Swedish subsidiary, Novavax AB. One of these, Matrix-M, is used in the Novavax COVID-19 vaccine. Wikipedia
Gestig
1987
Webwerf
Werknemers
952
